Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/257714
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group |
Autor: | Piñana, José Luis; López-Corral, L.; Martino, Rodrigo; Montoro, Juan; Vázquez-López, Lourdes; Pérez, Ariadna; Martin-Martin, Gabriel; Facal-Malvar, Ana; Ferrer, Elena; Pascual, M. Jesús CSIC ORCID; Sanz-Linares, Gabriela; Gago, Beatriz; Sánchez-Salinas, Andres; Villalón, Lucía; Conesa-Garcia, Venancio; Olave, María-Teresa; López-Jiménez, Javier; Marcos-Corrales, Sara; García-Blázquez, Sara; García-Gutiérrez, Valentín; Hernández-Rivas, José Ángel; Saus, Ana; Espigado, Ildefonso CSIC ORCID; Alonso, Carmen; Hernani, Rafael; Solano, Carlos; Ferrer-Lores, Blanca; Guerreiro, Manuel; Ruiz-García, María Montserrat; Muñoz-Bellido, Juan Luis; Navarro, David; Cedillo, Ángel; Sureda, Anna | Fecha de publicación: | ene-2022 | Editor: | John Wiley & Sons | Citación: | American Journal of Hematology 97(1): 30-42 (2022) | Resumen: | This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3–6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia < 1 × 109/ml (odds ratio [OR] 0.33, 95% confidence interval [95% CI] 0.16–0.69, p = .003), active graft versus host disease (GvHD; OR 0.51, 95% CI 0.27–0.98, p = .04) and vaccination within the first year of transplant (OR 0.3, 95% CI 0.15–0.9, p = .04) associated with lower antibody detection whereas. In ASCT, non-Hodgkin's lymphoma (NHL; OR 0.09, 95% CI 0.02–0.44, p = .003) and active corticosteroid therapy (OR 0.2, 95% CI 0.02–0.87, p = .03) were associated with lower detection rate. We report an encouraging rate of SARS-CoV-2-reactive antibodies detection in these severe immunocompromised patients. Lymphopenia, GvHD, the timing of vaccine, and NHL and corticosteroids therapy should be considered in allo-HSCT and ASCT, respectively, to identify candidates for SARS-CoV-2 antibodies monitoring. | Versión del editor: | https://doi.org/10.1002/ajh.26385 | URI: | http://hdl.handle.net/10261/257714 | DOI: | 10.1002/ajh.26385 | ISSN: | 0361-8609 | E-ISSN: | 1096-8652 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
49
checked on 10-abr-2024
WEB OF SCIENCETM
Citations
43
checked on 27-feb-2024
Page view(s)
83
checked on 22-abr-2024
Download(s)
22
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.